Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment

[1]  Falko Fend,et al.  Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.

[2]  T. Mattfeldt,et al.  Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  W. Oyen,et al.  18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients , 2007, Journal of Nuclear Medicine.

[4]  Eric O. Aboagye,et al.  Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Lehnert,et al.  Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET , 2007, Leukemia & lymphoma.

[7]  M. Schwaiger,et al.  PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  T. Mattfeldt,et al.  Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.

[9]  J. Ajani,et al.  Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models , 2006, Clinical Cancer Research.

[10]  Kyung-Ja Cho,et al.  Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  E. Aboagye,et al.  Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.

[13]  S. Faria,et al.  FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  P. Price,et al.  The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  A. van Waarde,et al.  Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  W. Vaalburg,et al.  Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine , 2004, Clinical Cancer Research.

[17]  Gerald Reischl,et al.  PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[19]  Bengt Långström,et al.  Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  W. Woods,et al.  DNA Damage Induces a Novel p53-Survivin Signaling Pathway Regulating Cell Cycle and Apoptosis in Acute Lymphoblastic Leukemia Cells , 2002, Journal of Pharmacology and Experimental Therapeutics.

[21]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  G. Glatting,et al.  Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  N. Avril,et al.  Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  H. Mano,et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.

[25]  S. Di Bartolomeo,et al.  Apoptosis Induced by Doxorubicin in Neurotumor Cells Is Divorced from Drug Effects on Ceramide Accumulation and May Involve Cell Cycle‐Dependent Caspase Activation , 2000, Journal of neurochemistry.

[26]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[27]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[29]  T K Lewellen,et al.  Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Elias S. J. Arnér,et al.  Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. , 1994, Advances in enzyme regulation.

[31]  T. Chou,et al.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.

[32]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Hirsh,et al.  Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management , 1989 .

[34]  P. Martiat,et al.  In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[36]  S. Siegel,et al.  Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. , 1976, Cancer research.